Zobrazeno 1 - 10 of 49 pro vyhledávání: '"Ingrid A Boere"'
1
Akademický článek
Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
Autor: Bernadette A M Heemskerk-Gerritsen, Antoinette Hollestelle, Christi J van Asperen, Irma van den Beek, Willemien J van Driel, Klaartje van Engelen, Encarna B Gómez Garcia, Joanne A de Hullu, Marco J Koudijs, Marian J E Mourits, Maartje J Hooning, Ingrid A Boere
Publikováno v: PLoS ONE, Vol 17, Iss 9, p e0275015 (2022)
IntroductionGermline BRCA1/2-associated epithelial ovarian cancer has been associated with better progression-free survival and overall survival than sporadic epithelial ovarian cancer, but conclusive data are lacking.MethodsWe matched 389 BRCA1-asso
Externí odkaz: https://doaj.org/article/78bf0cb2beca4827a30625f36863fc26
Zobrazit plný text záznamu
2
Akademický článek
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol
Autor: Phyllis van der Ploeg, Cynthia SE. Hendrikse, Anna MJ. Thijs, Hans M. Westgeest, Huberdina PM. Smedts, M Caroline Vos, Mathilde Jalving, Christianne AR. Lok, Ingrid A. Boere, Maaike APC. van Ham, Petronella B. Ottevanger, Anneke M. Westermann, Constantijne H. Mom, Roy I. Lalisang, Sandrina Lambrechts, Ruud LM. Bekkers, Jurgen MJ. Piek
Publikováno v: Heliyon, Vol 10, Iss 1, Pp e23170- (2024)
Objective: Ovarian cancer is the fifth cause of cancer-related death among women. The benefit of targeted therapy for ovarian cancer patients is limited even if treatment is stratified by molecular signature. There remains a high unmet need for alter
Externí odkaz: https://doaj.org/article/ec80d08ac0c84967956ced20e2dd05ff
Zobrazit plný text záznamu
3
Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands
Autor: Joosje H. Heimovaara, Ingrid A. Boere, Jorine de Haan, Kristel van Calsteren, Frédéric Amant, Lia van Zuylen, Christine A.R. Lok, C.A.R. Lok, L. van Zuylen, I.A. Boere, F. Amant, C.C.M. Beerendonk, M. Bellido-Casado, J.J. Beltman, M.E.M.M. Bos, J.J. Duvekot, C.G., Gerestein, S. Gordijn, C.J.M. de Groot, M. van Grotel, S.N. Han, B.C. Heeres, M.M. van den Heuvel-Eibrink, A. Houwink, D.R. Huitema, PhW. Koken, L.B. Koppert, P.J. Lugtenburg, P.B. Ottevanger, R.C. Painter, P.M.P. Poortmans, E.M. Roes, L. van der Scheer, C.P. Schröder, B.B.M. Suelmann, K.P.M. Suijkerbuijk, G. van Tienhoven, N.E. van Trommel, J.W. Trum, J. van der Velden, I.J.H. Vriens, P.O. Witteveen
Publikováno v: Heimovaara, J H, Boere, I A, de Haan, J, van Calsteren, K, Amant, F, van Zuylen, L, Lok, C A R, the Dutch Advisory Board for Cancer during Pregnancy, Lok, C A R, van Zuylen, L, Boere, I A, Amant, F, Beerendonk, C C M, Bellido-Casado, M, Beltman, J J, Bos, M E M M, Duvekot, J J, Gerestein, C G, Gordijn, S, de Groot, C J M, van Grotel, M, Han, S N, Heeres, B C, van den Heuvel-Eibrink, M M, Houwink, A, Huitema, D R, Koken, P, Koppert, L B, Lugtenburg, P J, Ottevanger, P B, Painter, R C, Poortmans, P M P, Roes, E M, van der Scheer, L, Schröder, C P, Suelmann, B B M, Suijkerbuijk, K P M, van Tienhoven, G, van Trommel, N E, Trum, J W, van der Velden, J, Vriens, I J H & Witteveen, P O 2022, ' Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands ', European Journal of Cancer, vol. 171, pp. 13-21 . https://doi.org/10.1016/j.ejca.2022.04.040
European Journal of Cancer, 171, 13-21. Pergamon
European Journal of Cancer, 171, 13-21. Elsevier Ltd.
European Journal of Cancer, 171, 13-21. ELSEVIER SCI LTD
European Journal of Cancer, 171, 13-21
European Journal of Cancer, 171, pp. 13-21
European Journal of Cancer, 171, 13-21. Elsevier Limited
Contains fulltext : 252036.pdf (Publisher’s version ) (Closed access) BACKGROUND: Most physicians encounter pregnant women with cancer incidentally, leading to a lack of expertise or confidence to inform and treat these patients based on the most r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb870c0ecb6e659780a111f08cb40158
https://doi.org/10.1016/j.ejca.2022.04.040
Zobrazit plný text záznamu
4
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
Autor: Eleni Karamouza, Rosalind M. Glasspool, Caroline Kelly, Liz-Anne Lewsley, Karen Carty, Gunnar B. Kristensen, Josee-Lyne Ethier, Tatsuo Kagimura, Nozomu Yanaihara, Sabrina Chiara Cecere, Benoit You, Ingrid A. Boere, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Cécile Proust-Lima, Xavier Paoletti
Publikováno v: Cancers, 15(6):1823. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers; Volume 15; Issue 6; Pages: 1823
(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients’ monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged indi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72838f055c8f5a58d2adf79cd12610d3
https://doi.org/10.3390/cancers15061823
Zobrazit plný text záznamu
5
The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis
Autor: Ruud L.M. Bekkers, Phyllis van der Ploeg, Sandrina Lambrechts, Jurgen M.J. Piek, Hans M. Westgeest, Anna M.J. Thijs, Aniek Uittenboogaard, Anja van de Stolpe, Ingrid A. Boere
Publikováno v: Gynecologic Oncology, 163(2), 433-444. Elsevier Science
Objective. To determine the clinical benefit of monotherapy with PI3K/AKT/mTOR inhibitors in patients diagnosed with advanced or recurrent ovarian cancer and to investigate the predictive value of current PI3K/AKT/ mTOR biomarkers on therapy response
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1d4a86c00b11c2413b6be3b738bbee7
https://doi.org/10.1016/j.ygyno.2021.07.008
Zobrazit plný text záznamu
8
The added value of H-2 antagonists in premedication regimens during paclitaxel treatment
Autor: Patricia M. L. A. van den Bemt, Ingrid A. Boere, Roelof W F van Leeuwen, Esther Oomen-de Hoop, Juul M. Cox, Tessa M. Bosch, Ruben Malmberg, Leni van Doorn, Agnes Jager, Ron H.J. Mathijssen
Publikováno v: British Journal of Cancer, 124(10), 1647-1652. Nature Publishing Group
Background: Ranitidine, a histamine 2 blocker, is the standard of care to prevent hypersensitivity reactions (HSRs) caused by paclitaxel infusion. However, the added value of ranitidine in this premedication regimen is controversial. Therefore, we co
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6cbfff37ed4074ce982e9b8d1d1b753
https://research.rug.nl/en/publications/298eb27d-ea6a-4185-b5c0-53296ae2c87b
Zobrazit plný text záznamu
9
Management of pregnancy in women with cancer
Autor: Charlotte Maggen, Ingrid A. Boere, Elyce Cardonick, Liesbeth Lenaerts, Joosje Heimovaara, Vera E. R. A. Wolters, Frédéric Amant
Publikováno v: International Journal of Gynecological Cancer
International Journal of Gynecological Cancer, 31(3), 314-322. BMJ Publishing Group
As the incidence of cancer in pregnancy has been increasing in recent decades, more specialists are confronted with a complex oncologic–obstetric decision-making process. With the establishment of (inter)national registries, including the Internati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3fa89aab9fad6538cc5b6ca3917d6d1
https://doi.org/10.1136/ijgc-2020-001776
Zobrazit plný text záznamu
10
Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls
Autor: Christina Bechtner, Hanne Lefrère, Andreas Schneeweiss, Sabine Schmatloch, Frédéric Amant, Valentina Nekljudova, Charlotte Maggen, Elyce Cardonick, Fenja Seither, Sibylle Loibl, Patrick Neven, Ingrid A. Boere, Jorine de Haan, Christine Solbach, Mina Mhallem Gziri, Tatjana Cordes, Sabine Seiler, Christianne A.R. Lok, Kristel Van Calsteren, Isabell Witzel
Publikováno v: European Journal of Cancer, 170, 54-63. Elsevier Ltd.
European Journal of Cancer, 170, 54-63. Elsevier Limited
European journal of cancer (Oxford, England : 1990), Vol. 170, no.1, p. 54-63 (2022)
515 Background: Overall a diagnosis of breast cancer during pregnancy (BCP) appears not to impact maternal prognosis if standard treatment is offered. However, caution is warranted as gestational changes in pharmacokinetics with respect to the distri
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98f1012ba7c3c23bfbb8e0510831565b
https://pubmed.ncbi.nlm.nih.gov/35594612
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje